Interprotein
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese biotech developing novel protein-protein interaction modulators using proprietary small molecule and peptide platforms to target undruggable interfaces.
OncologyImmunology
Technology Platform
INTENDD® platform for structure-based small molecule design targeting protein-protein interactions, complemented by helix-loop-helix peptide libraries for high-affinity peptide binders identified through phage display screening.
Opportunities
The vast untapped landscape of protein-protein interactions (130,000-650,000 putative targets) represents a major growth opportunity, particularly as traditional druggable targets become exhausted and biologics face limitations in administration and cost.
Risk Factors
Scientific risk of successfully drugging challenging PPI targets, competition from both small molecule platforms and advanced biologic approaches, and dependence on partnership funding for capital-intensive R&D.
Competitive Landscape
Competes with other PPI-focused companies like Nimbus Therapeutics and Relay Therapeutics, but differentiates through its dual small molecule/peptide modality and specialized INTENDD® platform optimized specifically for PPI interfaces.